WHO Drug Information, Vol. 21, No. 1, 2007
Recommended INN: List 57
International Nonproprietary Names for Pharmaceutical Substances (INN) RECOMMENDED International Nonproprietary Names: List 57 Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution EB15.R7); 1969, 173, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy. Lists of Proposed (1–91) and Recommended (1–52) International Nonproprietary Names can be found in Cumulative List No. 11, 2004 (available in CD-ROM only).
Dénominations communes internationales des Substances pharmaceutiques (DCI) Dénominations communes internationales RECOMMANDÉES: Liste 57 Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond. Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies par l’Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L’inclusion d’une dénomination dans les listes de DCI recommandées n’implique aucune recommandation en vue de l’utilisation de la substance correspondante en médecine ou en pharmacie. On trouvera d’autres listes de Dénominations communes internationales proposées (1–91) et recommandées (1–52) dans la Liste récapitulative No. 11, 2004 (disponible sur CD-ROM seulement).
Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI) Denominaciones Comunes Internacionales RECOMENDADAS: Lista 57 De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución EB15.R7); 1969, 173, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia. Las listas de Denominaciones Comunes Internacionales Propuestas (1–91) y Recomendadas (1–52) se encuentran reunidas en Cumulative List No. 11, 2004 (disponible sólo en CD-ROM).
53
Recommended INN: List 57
WHO Drug Information, Vol. 21, No. 1, 2007
Latin, English, French, Spanish: Recommended INN DCI Recommandée DCI Recomendada
Chemical name or description; Molecular formula; Graphic formula Nom chimique ou description; Formule brute; Formule développée Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada
abagovomabum* abagovomab
immunoglobulin G1, anti-idiotype anti-[anti-(Homo sapiens cancer antigen 125, CA 125, MUC-16) Mus musculus monoclonal antibody OC125] Mus musculus monoclonal antibody ACA125, clone 3D5 gamma1 heavy chain disulfide with clone 3D5 kappa light chain; (223-223'':226-226'':228-228'') trisdisulfide dimer immunoglobuline G1, anti-idiotype anti-[anti-(Homo sapiens cancer antigen 125, CA 125, MUC-16) anticorps monoclonal murin OC125] anticorps monoclonal murin ACA125, chaîne lourde gamma1 du clone 3D5 unie par un pont disulfure à la chaîne légère kappa du clone 3D5; dimère (223-223'':226-226'':228-228'')-trisdisulfure inmunoglobulina G1, anti-idiotipo anti-[anti-(Homo sapiens cancer antígeno 125, CA 125, MUC-16) anticuerpo monoclonal murino OC125] anticuerpo monoclonal murino ACA125, cadena pesada gamma1 del clon 3D5 unida por un puente disulfuro a la cadena ligera kappa del clon 3D5; dímero (223-223'':226-226'':228-228'')trisdisulfuro Heavy chain/Chaîne lourde/Cadena pesada QVKLQESGAE LARPGASVKL SCKASGYTFT IYPGDGNTRY THKFKGKATL TADKSSSTAY GNYAWFAYWG QGTTVTVSSA KTTPPSVYPL YFPEPVTVTW NSGSLSSGVH TFPAVLQSDL CNVAHPASST KVDKKIVPRD CGCKPCICTV LTPKVTCVVV DISKDDPEVQ FSWFVDDVEV ELPIMHQDWL NGKEFKCRVN SAAFPAPIEK KEQMAKDKVS LTCMITDFFP EDITVEWQWN FVYSKLNVQK SNWEAGNTFT CSVLHEGLHN Light chain/Chaîne légère/Cadena ligera DIELTQSPAS LSASVGETVT ITCQASENIY AKTLAGGVSS RFSGSGSGTH FSLKIKSLQP GTKLEIKRAD AAPTVSIFPP SSEQLTSGGA DGSERQNGVL NSWTDQDSKD STYSMSSTLT STSPIVKSFN RNEC
abagovomab
abagovomab
NYWMQWVKQR MQLSSLASED APGSAAQTNS YTLSSSVTVP PEVSSVFIFP HTAQTQPREE TISKTKGRPK GQPAENYKNT HHTEKSLSHS
PGQGLDWIGA SGVYYCARGE MVTLGCLVKG SSTWPSETVT PKPKDVLTIT QFNSTFRSVS APQVYTIPPP QPIMDTDGSY PGK
50 100 150 200 250 300 350 400 443
SYLAWHQQKQ EDFGIYYCQH SVVCFLNNFY LTKDEYERHN
GKSPQLLVYN HYGILPTFGG PKDINVKWKI SYTCEATHKT
50 100 150 200 214
acidum iodofilticum ( 123 iodofiltic acid ( I) acide iodofiltique ( ácido iodofíltico ( 123
123
I) (3RS)-15-[4-[
123
I]iodophenyl]3-methylpentadecanoic acid 123
I)
acide (3RS)-15-(4-[ ácido (3RS)-15-(4-[ C22H35 123
I]iodophényl)-3-méthylpentadécanoïque I]iodofenil)-3-metilpentadecanoico
123
I)
123
IO2 H CH3 CO2H
[123I]
and enantiomer et énantiomère y enantiómero
54
WHO Drug Information, Vol. 21, No. 1, 2007
Recommended INN: List 57
aclidinii bromidum aclidinium bromide
(3R)-3-[(hydroxy)di(thiophen-2-yl)acetyloxy]-1-(3-phenoxypropyl)1λ -azabicyclo[2.2.2]octan-1-ylium bromide 5
bromure d’aclidinium bromuro de aclidinio
bromure de (3R)-3-[[hydroxybis(thiophén-2-yl)acétyl]oxy]1-(3-phénoxypropyl)-1-azoniabicyclo[2.2.2]octane bromuro de (3R)-1-(3-fenoxipropil)-3-[(hidroxi)di(tiofen-2-il)acetiloxi]1λ -azabiciclo[2.2.2]octan-1-ilio C26H30BrNO4S2 S O H O S OH N+ BrO 5
afimoxifenum afimoxifene afimoxifène afimoxifeno
4-(1-{4-[2-(dimethylamino)ethoxy]phenyl}-2-phenylbut-1-enyl)phenol 4-[1-[4-[2-(diméthylamino)éthoxy]phényl]-2-phénylbut-1-ényl]phénol 4-[1-[4-[2-(dimetilamino)etoxi]fenil]-2-fenilbut-1-enil]fenol C26H29NO2 H3C O N CH3
CH3 and Z isomer et l'isomère Z y el isómero Z
OH
afliberceptum* aflibercept
des-432-lysine-[human vascular endothelial growth factor receptor 1-(103-204)-peptide (containing Ig-like C2-type 2 domain) fusion protein with human vascular endothelial growth factor receptor 2-(206-308)-peptide (containing Ig-like C2-type 3 domain fragment) fusion protein with human immunoglobulin G1-(227 C-terminal residues)-peptide (Fc fragment)], (211-211':214-214')-bisdisulfide dimer (211-211':214-214')-bisdisulfure du dimère de la dès-432-lysine[récepteur 1 humain du facteur de croissance endothélial vasculaire(103-204)-peptide (contenant le domaine Ig-like C2-type 2) protéine de fusion avec le récepteur 2 humain du facteur de croissance endothélial vasculaire-(206-308)-peptide (contenant un fragment du domaine Ig-like C2-type 3) protéine de fusion avec l’immunoglobuline G1 humaine-(227 résidus C-terminaux)-peptide (fragment Fc)]
aflibercept
55
Recommended INN: List 57
WHO Drug Information, Vol. 21, No. 1, 2007
aflibercept
(211-211':214-214')-bisdisulfuro del dímero de la des-432-lisina[receptor 1 humano del factor de crecimiento endotelial vascular(103-204)-péptido (que contiene el dominio Ig-like C2-tipo 2) proteína de fusión con el receptor 2 humano del factor de crecimiento endotelial vascular-(206-308)-péptido (que contiene un fragmento del dominio Ig-like C2-tipo 3) proteína de fusión con la inmunoglobulina G1 humana-(227 restos C-terminales)-péptido (fragmento Fc)] C4318H6788N1164O1304S32 Monomer / Monomère / Monómero SDTGRPFVEM YSEIPEIIHM TEGRELVIPC PDGKRIIWDS RKGFIISNAT YKEIGLLTCE IIDVVLSPSH GIELSVGEKL VLNCTARTEL VNRDLKTQSG SEMKKFLSTL TIDGVTRSDQ RVHEKDKTHT CPPCPAPELL GGPSVFLFPP VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ GKEYKCKVSN KALPAPIEKT ISKAKGQPRE TCLVKGFYPS DIAVEWESNG QPENNYKTTP RWQQGNVFSC SVMHEALHNH YTQKSLSLSP RVTSPNITVT ATVNGHLYKT NVGIDFNWEY GLYTCAASSG KPKDTLMISR YNSTYRVVSV PQVYTLPPSR PVLDSDGSFF G LKKFPLDTLI NYLTHRQTNT PSSKHQHKKL LMTKKNSTFV TPEVTCVVVD LTVLHQDWLN DELTKNQVSL LYSKLTVDKS 50 100 150 200 250 300 350 400 431
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 30-79 30'-79' 124-185 124'-185' 211-211' 214-214' 246-306 246'-306' 352-410 352'-410'
aleglitazarum aleglitazar aléglitazar aleglitazar
(2S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]1-benzothiophen-7-yl}propanoic acid acide (2S)-2-méthoxy-3-[4-[2-(5-méthyl-2-phényl-1,3-oxazol4-yl)éthoxy]-1-benzothiophén-7-yl]propanoïque ácido (2S)-3-{4-[2-(2-fenil-1,3-oxazol-5-metil-4-il)etoxi]1-benzotiofen-7-il}-2-metoxipropanoico C24H23NO5S N O CH3 S O CH3 O H CO2H
alferminogenum tadenovecum* alferminogene tadenovec
recombinant human adenovirus 5 (replication-deficient, E1-deleted) containing a human fibroblast growth factor-4 cDNA sequence driven by a cytomegalovirus promoter adénovirus 5 humain recombinant (réplication-déficient, région E1supprimée) contenant la séquence ADN-copie du facteur 4 de croissance du fibroblaste humain sous contrôle d’un promoteur de cytomégalovirus adenovirus 5 humano recombinante (replicación-deficiente, con delección E1) que contiene la secuencia DNA-copia del factor-4 de crecimiento de fibroblastos humanos controlado por un promotor de citomegalovirus
alferminogène tadénovec
alferminogén tadenovec
56
WHO Drug Information, Vol. 21, No. 1, 2007
Recommended INN: List 57
apilimodum apilimod apilimod apilimod
1-[(3-methylphenyl)methylidene]-2-{6-(morpholin-4-yl)-2-[2-(pyridin2-yl)ethoxy]pyrimidin-4-yl}hydrazine 1-(3-méthylbenzylidène)-2-[6-(morpholin-4-yl)-2-[2-(pyridin-2-yl)= éthoxy]pyrimidin-4-yl]diazane 1-(3-metilbencilideno)-2-[6-(morfolin-4-il)-2-[2-(piridin-2-il)etoxi]= pirimidin-4-il]diazano C23H26N6O2 N O N N CH3 O N H N
N
apricitabinum apricitabine apricitabine apricitabina
4-amino-1-[(2R,4R)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl]pyrimidin2(1H)-one (-)-4-amino-1-[(2R,4R)-2-(hydroxyméthyl)-1,3-oxathiolan-4-yl]= pyrimidin-2(1H)-one (-)-4-amino-1-[(2R,4R)-2-(hidroximetil)-1,3-oxatiolan-4-il]pirimidin2(1H)-ona C8H11N3O3S O HO S H O N H N NH2
artemisonum artemisone
4-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimethyldecahydro12H-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10-yl]= thiomorpholine-1,1-dione 1,1-dioxyde de 4-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9triméthyldécahydro-3,12-époxypyrano[4,3-j]-1,2-benzodioxépin10-yl]thiomorpholine 1,1-dióxido de 4-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9trimetildecahidro-3,12-epoxipirano[4,3-j]-1,2-benzodioxepin-10-il]= tiomorfolina
artémisone
artemisona
57
Recommended INN: List 57
WHO Drug Information, Vol. 21, No. 1, 2007
C19H31NO6S O CH3 H H H H3C H O O O O H S O N H
CH3
ataciceptum* atacicept
[86-serine,101-glutamic acid,196-serine,197-serine,222-aspartic acid,224-leucine][human tumor necrosis factor receptor superfamily member 13B-(30-110)-peptide (TACI fragment containing TNFR-Cys 1 and TNFR-Cys 2) fusion protein with human immunogobulin G1(232 C-terminal residues)-peptide (γ1-chain Fc fragment), (92-92':9595')-bisdisulfide dimer (92-92':95-95')-bisdisulfure du dimère de la [86-sérine,101-acide glutamique,196-sérine,197-sérine,222-acide aspartique, 224-leucine]-protéine de fusion du membre 13B humain de la superfamille des récepteurs du facteur de nécrose tumorale(30-110)-peptide (portion du TACI incluant les deux régions riches en cystéine) avec l’immunoglobuline G1 humaine-(232 résidus C-terminaux)-peptide (fragment Fc de la chaîne γ1) 92-92':95-95')-bisdisulfuro del dímero de la [86-serina,101-ácido glutámico,196-serina,197-serina,222-ácido aspártico,224-leucina]proteína de fusión del miembro 13B humano de la superfamilia de receptores del factor de necrosis tumoral-(30-110)-péptido (porción del TACI que incluye las dos regiones ricas en cisteína) con la inmunoglobulina G1 humana-(232 restos C-terminales)-péptido (fragmento Fc de la cadena γ1) C3104H4788N856O950S44 Monomer / Monomère / Monómero AMRSCPEEQY WDPLLGTCMS CKTICNHQSQ DHLLRDCISC ASICGQHPKQ CAYFCENKLR EGAPSVFLFP PKPKDTLMIS RTPEVTCVVV HNAKTKPREE QYNSTYRVVS VLTVLHQDWL TISKAKGQPR EPQVYTLPPS RDELTKNQVS GQPENNYKTT PPVLDSDGSF FLYSKLTVDK HYTQKSLSLS PGK RTCAAFCRSL SEPKSSDKTH DVSHEDPEVK NGKEYKCKVS LTCLVKGFYP SRWQQGNVFS SCRKEQGKFY TCPPCPAPEA FNWYVDGVEV NKALPSSIEK SDIAVEWESN CSVMHEALHN 50 100 150 200 250 300 313
atacicept
atacicept
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 5-18 5'-18' 21-33 21'-33' 25-37 25'-37' 42-57 42'-57' 60-71 60'-71' 64-75 64'-75' 92-92' 95-95' 127-187 127'-187' 233-291 233'-291'
azilsartanum azilsartan azilsartan azilsartán
2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)1,1'-biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid acide 2-éthoxy-1-[[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)= biphényl-4-yl]méthyl]-1H-benzimidazole-7-carboxylique ácido 2-etoxi-1-{[2'-(5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil4-il]metil}-1H-bencimidazol-7-carboxílico
58
WHO Drug Information, Vol. 21, No. 1, 2007
Recommended INN: List 57
C25H20N4O5 CO2H N N O CH3 O O HN N
bavituximabum* bavituximab
immunoglobulin G1, anti-(phosphatidylserine) chimeric monoclonal ch3G4; gamma1 heavy chain (Mus musculus VH-Homo sapiens IGHG1) (223-214')-disulfide with kappa light chain (Mus musculus V-KAPPA-Homo sapiens IGKC); (229-229'':232-232'')-bisdisulfide dimer immunoglobuline G1, anti-(phosphatidylsérine) anticorps monoclonal chimérique ch3G4; chaîne lourde gamma1 (Mus musculus VHHomo sapiens IGHG1) (223-214')-disulfure avec la chaîne légère kappa (Mus musculus V-KAPPA-Homo sapiens IGKC); dimère (229-229'':232-232'')-bisdisulfure inmunoglobulina G1, anti-(fosfatidilserina) anticuerpo monoclonal quimérico ch3G4; cadena pesada gamma1 (Mus musculus VHHomo sapiens IGHG1) (223-214')-disulfuro con la cadena ligera kappa (Mus musculus V-KAPPA-Homo sapiens IGKC), dímero (229-229'':232-232'')-bisdisulfuro C6446H9946N1702O2042S42 Heavy chain / Chaîne lourde / Cadena pesada EVQLQQSGPE LEKPGASVKL SCKASGYSFT IDPYYGDTSY NQKFRGKATL TVDKSSSTAY YYGHWYFDVW GAGTTVTVSS ASTKGPSVFP DYFPEPVTVS WNSGALTSGV HTFPAVLQSS YICNVNHKPS NTKVDKKVEP KSCDKTHTCP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW STYRVVSVLT VLHQDWLNGK EYKCKVSNKA VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV k Chain / Chaîne k / Cadena k DIQMTQSPSS LSASLGERVS TSSLDSGVPK RFSGSRSGSD GTKLELKRAD AAPSVFIFPP DNALQSGNSQ ESVTEQDSKD LSSPVTKSFN RGEC LTCRASQDIG YSLTISSLES SDEQLKSGTA STYSLSSTLT GYNMNWVKQS MQLKSLTSED LAPSSKSTSG GLYSLSSVVT PCPAPELLGG YVDGVEVHNA LPAPIEKTIS AVEWESNGQP MHEALHNHYT SSLNWLQQGP EDFVDYYCLQ SVVCLLNNFY LSKADYEKHK HGKSLEWIGH SAVYYCVKGG GTAALGCLVK VPSSSLGTQT PSVFLFPPKP KTKPREEQYN KAKGQPREPQ ENNYKTTPPV QKSLSLSPGK DGTIKRLIYA YVSSPPTFGA PREAKVQWKV VYACEVTHQG 50 100 150 200 250 300 350 400 450
bavituximab
bavituximab
50' 100' 150' 200' 214'
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 22-96 22''-96'' 23'-88' 23'''-88''' 134'-194' 134'''-194''' 147-203 147''-203'' 214'-223 214'''-223'' 229-229'' 232-232'' 264-324 264''-324'' 370-428 370''-428''
59
Recommended INN: List 57
WHO Drug Information, Vol. 21, No. 1, 2007
bedoradrinum bedoradrine
2-{[(7S)-7-({(2R)-2-hydroxy-2-[4-hydroxy-3-(2-hydroxyethyl)phenyl]= ethyl}amino)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}N,N-dimethylacetamide (-)-2-[[(7S)-7-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(2-hydroxyéthyl)= phényl]éthyl]amino]-5,6,7,8-tétrahydronaphtalén-2-yl]oxy]N,N-diméthylacétamide (-)-2-{[(7S)-7-({(2R)-2-hidroxi-2-[4-hidroxi-3-(2-hidroxietil)fenil]= etil}amino)-5,6,7,8-tetrahidronaftalen-2-il]oxi}-N,N-dimetilacetamida C24H32N2O5 H OH H N H HO OH O O N CH3
bédoradrine
bedoradrina
CH3
beperminogenum perplasmidum* beperminogene perplasmid béperminogène perplasmide
plasmid DNA containing human hepatocyte growth factor cDNA sequence driven by a cytomegalovirus promoter ADN plasmidique contenant la séquence ADN-copie du facteur de croissance de l’hépatocyte humain sous contrôle d’un promoteur de cytomégalovirus DNA de plásmido que contiene la secuencia DNA-copia del factor de crecimiento del hepatocito humano controlado por un promotor de citomegalovirus
beperminogén perplásmido
beroctocogum alfa* beroctocog alfa béroctocog alfa
human blood-coagulation factor VIII-(1-740)-peptide complex with human blood-coagulation factor VIII-(1649-2332)-peptide combinaison du facteur VIII de coagulation humain-(1-740)-peptide (chaîne lourde du facteur VIIIa, isoforme de 92 kDa) avec le facteur VIII de coagulation humain-(1649-2332)-peptide (chaîne légère du facteur VIIIa) combinación del factor VIII de coagulación humano-(1-740)-péptido (cadena pesada del factor VIIIa, isoforma de 92 kDa) con el factor VIII de coagulación humano-(1649-2332)-péptido (cadena ligèra del factor VIIIa)
beroctocog alfa
60
WHO Drug Information, Vol. 21, No. 1, 2007
Recommended INN: List 57
C3821H5813N1003O1139S35 + C3553H5400N956O1032S35 Heavy chain / Chaîne lourde / Cadena pesada ATRRYYLGAV ELSWDYMQSD LGELPVDARF FVEFTDHLFN IAKPRPPWMG LLGPTIQAEV VGVSYWKASE GAEYDDQTSQ REKEDDKVFP PLCLTYSYLS HVDLVKDLNS GLIGALLVCR VFDEGKSWHS ETKNSLMQDR DAASARAWPK KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN MDLGQFLLFC HISSHQHDGM EAYVKVDSCP TDSEMDVVRF DDDNSPSFIQ IRSVAKKHPK APDDRSYKSQ YLNNGPQRIG RKYKKVRFMA PLLYGEVGDT LLIIFKNQAS RPYNIYPHGI FPILPGEIFK YKWTVTVEDG PTKSDPRCLT LLICYKESVD QRGNQIMSDK RNVILFSVFD VQLEDPEFQA SNIMHSINGY VFDSLQLSVC VFFSGYTFKH KMVYEDTLTL FPFSGETVFM GMTALLKVSS CDKNTGDYYE DSYEDISAYL Light chain / Chaîne légère / Cadena ligera TRTTLQSDQE AAVERLWDYG ELNEHLGLLG EPRKNFVKPN LIGPLLVCHT APCNIQMEDP ENIHSIHFSG LIGEHLHAGM ARLHYSGSIN FIIMYSLDGK LHPTHYSIRS ATWSPSKARL LLTSMYVKEF LLTRYLRIHP EIDYDDTISV MSSSPHVLRN PYIRAEVEDN ETKTYFWKVQ NTLNPAHGRQ TFKENYRFHA HVFTVRKKEE STLFLVYSNK AWSTKEPFSW KWQTYRGNST TLRMELMGCD HLQGRSNAWR LISSSQDGHQ QSWVHQIALR EMKKEDFDIY RAQSGSVPQF IMVTFRNQAS HHMAPTKDEF VTVQEFALFF INGYIMDTLP YKMALYNLYP CQTPLGMASG IKVDLLAPMI GTLMVFFGNV LNSCSMPLGM PQVNNPKEWL WTLFFQNGKV MEVLGCEAQD DEDENQSPRS KKVVFQEFTD RPYSFYSSLI DCKAWAYFSD TIFDETKSWY GLVMAQDQRI GVFETVEMLP HIRDFQITAS IHGIKTQGAR DSSGIKHNIF ESKAISDAQI QVDFQKTMKV KVFQGNQDSF LY EI 1650 FQKKTRHYFI 1700 GSFTQPLYRG 1750 SYEEDQRQGA 1800 VDLEKDVHSG 1850 FTENMERNCR 1900 RWYLLSMGSN 1950 SKAGIWRVEC 2000 GQYGQWAPKL 2050 QKFSSLYISQ 2100 NPPIIARYIR 2150 TASSYFTNMF 2200 TGVTTQGVKS 2250 TPVVNSLDPP 2300 2332
PPRVPKSFPF YDTVVITLKN GGSHTYVWQV EGSLAKEKTQ MHTVNGYVNR HRQASLEISP EEPQLRMKNN TWVHYIAAEE YTDETFKTRE TDVRPLYSRR RYYSSFVNME ENRSWYLTEN LHEVAYWYIL SMENPGLWIL LSKNNAIEPR
NTSVVYKKTL MASHPVSLHA LKENGPMASD TLHKFILLFA SLPGLIGCHR ITFLTAQTLL EEAEDYDDDL EDWDYAPLVL AIQHESGILG LPKGVKHLKD RDLASGLIGP IQRFLPNPAG SIGAQTDFLS GCHNSDFRNR S
50 100 150 200 250 300 350 400 450 500 550 600 650 700 741
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 153-179 528-554 1899-1903 2021-2169 2174-2326
Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación Asn-41 Asn-239 Asn-582 Asn-1810 Asn-2118
Modifications / Modificaciones Y = 4-O-sulfotyrosyl
bremelanotidum bremelanotide brémelanotide bremelanotida
2,7-anhydro(N-acetyl-L-2-aminohexanoyl-L-aspartyl-L-histidylD-phenylalanyl-L-arginyl-L-tryptophyl-L-lysine) N-acétyl-L-2-aminohexanoyl-L-α-aspartyl-L-histidyl-D-phénylalanylL-arginyl-L-tryptophyl-L-lysine-(2→7)-lactame N-acetil-L-2-aminohexanoil-L-α-aspartil-L-histidil-D-fenilalanilL-arginil-L-triptofil-L-lisina-(2→7)-lactama C50H68N14O10 O H3C O H3 C N H H N H H L-His D-Phe L-Arg L-Trp N
NH H H CO2H
O
O
61
Recommended INN: List 57
WHO Drug Information, Vol. 21, No. 1, 2007
bucelipasum alfa* bucelipase alfa bucélipase alfa bucelipasa alfa
human bile-salt-activated lipase (cholesterol esterase, EC 3.1.1.13), glycoform alfa (recombinant hBSSL) lipase activée par les sels biliaires humaine (cholestérol estérase, EC 3.1.1.13), glycoforme alpha (recombinante hBSSL) lipasa humana activada por las sales biliares (colesterol esterasa, EC 3.1.1.13), glicoforma alfa (recombinante hBSSL) C3434H5258N894O1041S17 AKLGAVYTEG WQGTLKAKNF MIWIYGGAFL LSTGDANLPG SLQTLSPYNK AARMAQCLKV INLYANAADI FTITKGLRGA LAQHRANAKS TGYRPQDRTV ITKKMGSSSM VPPTGDSETA SGAPPVPPTG PPTGDSGAPP EAAPVPPTDD 64-80 246-257
GFVEGVNKKL KKRCLQATIT MGSGHGANFL NYGLRDQHMA GLIRRAISQS TDPRALTLAY DYIAGTNNMD KTTFDVYTES AKTYAYLFSH SKAMIAYWTN KRSLRTNFLR PVPPTGDSGA DSGAPPVPPT VPPTGDSGAP SKEAQMPAVI
GLLGDSVDIF QDSTYGDEDC NNYLYDGEEI IAWVKRNIAA GVALSPWVIQ KVPLAGLEYP GHIFASIDMP WAQDPSQENK PSRMPVYPKW FAKTGDPNMG YWTLTYLALP PPVPPTGDSG GDSGAPPVPP PVTPTGDSET RF
KGIPFAAPTK LYLNIWVPQG ATRGNVIVVT FGGDPNNITL KNPLFWAKKV MLHYVGFVPV AINKGNKKVT KKTVVDFETD VGADHADDIQ DSAVPTHWEP TVTDQEATPV APPVPPTGDS TGDSGAPPVP APVPPTGDSG
ALENPQPHPG RKQVSRDLPV FNYRVGPLGF FGESAGGASV AEKVGCPVGD IDGDFIPADP EEDFYKLVSE VLFLVPTEIA YVFGKPFATP YTTENSGYLE PPTGDSEATP GAPPVPPTGD PTGDAGPPPV APPVPPTGDS
50 100 150 200 250 300 350 400 450 500 550 600 650 700 722
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación Asn-187 Thr-538 Thr-549 Thr-559 Thr-576 Thr-587 Thr-598 Thr-609 Thr-620 Thr-631 Thr-642
camobucolum camobucol camobucol camobucol
4-{4-[(2-{[3,5-di(tert-butyl)-4-hydroxyphenyl]sulfanyl}propan-2-yl)= sulfanyl]-2,6-di(tert-butyl)phenoxy}acetic acid acide 4-{4-[(2-{[3,5-di(tert-butyl)-4-hydroxyphényl]sulfanyl}propan2-yl)sulfanyl]-2,6-di(tert-butyl)phénoxy}acétique ácido 4-{4-[(2-{[3,5-di(terc-butil)4-hidroxifenil]sulfanil}propan-2-il)= sulfanil]-2,6-di(terc-butil)fenoxi}acético C33H50O4S2 H3 C HO H3C H3C CH3 CH3 CH3 H3C S H3C H3 C CH3 S H3C CH3 O CO2H CH3 CH3
capadenosonum capadenoson capadénoson capadenosón
2-amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitrile 2-amino-6-[[[2-(4-chlorophényl)-1,3-thiazol-4-yl]méthyl]sulfanyl]4-[4-(2-hydroxyéthoxy)phényl]pyridine-3,5-dicarbonitrile 2-amino-6-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}sulfanil)4-[4-(2-hidroxietoxi)fenil]piridina-3,5-dicarbonitrilo
62
WHO Drug Information, Vol. 21, No. 1, 2007
Recommended INN: List 57
C25H18ClN5O2S2 NH2 N N Cl S S CN O OH CN
catramilastum catramilast catramilast catramilast
1-{(2S)-2-[3-(cyclopropylmethoxy)-4-methoxyphenyl]propyl}1,3-dihydro-2H-imidazol-2-one 1-[(2S)-2-[3-(cyclopropylméthoxy)-4-méthoxyphényl]propyl]1,3-dihydro-2H-imidazol-2-one 1-{(2S)-2-[3-(ciclopropilmetoxi)-4-metoxifenil]propil}-1,3-dihidro2H-imidazol-2-ona C17H22N2O3 H3CO O H CH3 N O NH
cediranibum cediranib cédiranib cediranib
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin1-yl)propoxy]quinazoline 4-[(4-fluoro-2-méthyl-1H-indol-5-yl)oxy]-6-méthoxy-7-[3-(pyrrolidin1-yl)propoxy]quinazoline 4-[(4-fluoro-2-metil-1H-indol-5-il)oxi]-6-metoxi-7-[3-(pirrolidin-1-il)= propoxi]quinazolina C25H27FN4O3 N N O N O OCH3 F H N CH3
denibulinum denibulin dénibuline denibulina
methyl [5-({4-[(2S)-2-aminopropanamido]phenyl}sulfanyl)1H-benzimidazol-2-yl]carbamate [5-[[4-[[(2S)-2-aminopropanamido]phenyl]sulfanyl]-1H-benzimidazol2-yl]carbamate de méthyle [5-({4-[(2S)-2-aminopropanamido]fenil}sulfanil)-1H-bencimidazol2-il]carbamato de metilo
63
Recommended INN: List 57
WHO Drug Information, Vol. 21, No. 1, 2007
C18H19N5O3S H H3C O NH2 H N S H N N O O NH CH3
dexelvucitabinum dexelvucitabine dexelvucitabine dexelvucitabina
4-amino-5-fluoro-1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran2-yl]pyrimidin-2(1H)-one (+)-4-amino-5-fluoro-1-[(2R,5S)-5-(hydroxyméthyl)-2,5-dihydrofuran2-yl]pyrimidin-2(1H)-one (+)-4-amino-5-fluoro-1-[(2R,5S)-5-(hidroximetil)-2,5-dihidrofuran2-il]pirimidin-2(1H)-ona C9H10FN3O3 O HO O N N NH2 F
efungumabum* efungumab
immunoglobulin scFv fragment, anti-(heat shock protein 90 homolog from Candida albicans (yeast)), methionylalanyl-[human monoclonal HSP90mab VH domain (120 residues)]-tris[(tetraglycyl)seryl]-[human monoclonal HSP90mab V-KAPPA domain (107 residues)]-[arginyltrialanyl-leucyl-glutamyl]-hexahistidine immunoglobuline fragment scFv, anti-(homologue de la protéine de choc thermique 90 de Candida albicans (levure)), methionylalanyl[domaine VH (120 residus) de l’anticorps monoclonal humain HSP90mab]-tris[(tetraglycyl)seryl]-[domaine V-KAPPA (107 residus) de l’anticorps monoclonal humain HSP90mab]-[arginyl-trialanylleucyl-glutamyl]-hexahistidine inmunoglobulina fragmento scFv, anti-(homólogo de la proteína de choc térmico 90 de Candida albicans ), metionilalanil-[dominio VH (120 restos) del anticuerpo monoclonal humano HSP90mab]tris[(tetraglicil)seril]-[dominio V-KAPPA (107 restos) del anticuerpo monoclonal humano HSP90mab]-[arginil-trialanil-leucil-glutamil]hexahistidina
éfungumab
efungumab
MAEVQLVES MGKIDPGDSY RGGRDFGDSF AFVGDRITIT SGSGSGTEFT LEhhhhhh
GAEVKKPGES INYSPSFQGH DYWGQGTLVT CRASSGISRY LTINSLQPED
LRISCKGSGC VTISADKSIN VSSGGGGSGG LAWYQQAPGK FATYYCQHLN
IISSYWISWV TAYLQWNSLK GGSGGGGSDV APKLLIYAAS SYPLTFGGGT
RQMPGKGLEW ASDTAMYYCA VMTQSPSFLS TLQTGVPSRF KVDIKRAAA
64
WHO Drug Information, Vol. 21, No. 1, 2007
Recommended INN: List 57
elocalcitolum elocalcitol élocalcitol
(1S,3R,5Z,7E,23E)-1-fluoro-26,27-dihomo-9,10-secocholesta5,7,10(19),16,23-pentaene-3,25-diol (1R,5S)-3-[(1Z)-2-[(3aS,4E,7aS)-1-[(1S,3E)-5-éthyl-5-hydroxy1-méthylhept-3-ényl]-7a-méthyl-3,3a,5,6,7,7a-hexahydro-4H-indén4-ylidène]éthylidène]-5-fluoro-4-méthylidènecyclohexanol (1S,3R,5Z,7E,23E)-1-fluoro-26,27-dihomo-9,10-secocolesta5,7,10(19),16,23-pentaeno-3,25-diol C29H43FO2 H3C H CH3 OH CH3
elocalcitol
CH3
H CH2 HO H H F
elsibucolum elsibucol elsibucol elsibucol
4-{4-[(2-{[3,5-di-tert-butyl-4-hydroxyphenyl]sulfanyl}propan-2-yl)= sulfanyl]-2,6-di-tert-butylphenoxy}butanoic acid acide 4-[4-[[1-[[3,5-bis(1,1-diméthyléthyl)-4-hydroxyphényl]sulfanyl]1-méthyléthyl]sulfanyl]-2,6-bis(1,1-diméthyléthyl)phénoxy]butanoïque ácido 4-{4-[(2-{[3,5-di-terc-butil-4-hidroxifenil]sulfanil}propan-2-il)= sulfanil]-2,6-di-terc-butilfenoxi}butanoico C35H54O4S2 H3C HO H3 C H3C CH3 CH3 CH3 H3C S H3C H3C CH3 S H3C CH3 O CH3 CH3 CO2H
epoetinum theta epoetin theta époétine thêta epoetina zeta
human erythropoietin-(1-165)-peptide, glycoform θ érythropoïétine humaine-(1-165)-peptide, glycoforme θ eritropoyetina humana-péptido-(1-165), glicoforma θ C809H1301N229O240S5
65
Recommended INN: List 57
WHO Drug Information, Vol. 21, No. 1, 2007
ferroquinum ferroquine ferroquine ferroquina
N'-(7-chloroquinolin-4-yl)-N,N-dimethyl-C,C'-(ferrocene-1,2-diyl)= dimethanamine N'-(7-chloroquinoléin-4-yl)-N,N-diméthyl-C,C'-(férrocène-1,2-diyl)= diméthanamine N'-(7-cloroquinolin-4-il)-N,N-dimetil-C,C'-(ferroceno-1,2-diil)= dimetanamina C23H24ClFeN3 Cl N
HN CH3 Fe N CH3
fluticasonum furoas fluticasone furoate furoate de fluticasone furoato de fluticasona
6α,9-difluoro-17{[(fluoromethyl)sulfanyl]carbonyl}-11β-hydroxy16α-methyl-3-oxoandrosta-1,4-dien-17α-yl furan-2-carboxylate furane-2-carboxylate de 6α,9-difluoro-17-[[(fluorométhyl)sulfanyl]= carbonyl]-11β-hydroxy-16α-méthyl-3-oxoandrosta-1,4-dién-17α-yle furano-2-carboxilato de 6α,9-difluoro-17-[[(fluorometil)sulfanil]= carbonil]-11β-hidroxi-16α-metil-3-oxoandrosta-1,4-dien-17α-ilo C27H29F3O6S O HO H H H F CH3 F O
S
CH3 F O H
O CH3 O H
fosalvudinum tidoxilum fosalvudine tidoxil
(2RS)-2-(decyloxy)-3-[(dodecyl)sulfanyl]propyl [(2R,3S,5R)-3-fluoro5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran2-yl]methyl hydrogen phosphate hydrogénophosphate de (2RS)-2-(décyloxy)-3-(dodécylsulfanyl)= propyle et de [(2R,3S,5R)-3-fluoro-5-(5-méthyl-2,4-dioxo3,4-dihydropyrimidin-1(2H)-yl)tétrahydrofuran-2-yl]méthyle hidrógenofosfato de (2RS)-2-(deciloxi)-3-[(dodecil)sulfanil]propilo y [(2R,3S,5R)-3-fluoro-5-(5-metil-2,4-dioxo-3,4-dihidropirimidin1(2H)-il)tetrahidrofuran-2-il]metilo
fosalvudine tidoxil
fosalvudina tidoxilo
66
WHO Drug Information, Vol. 21, No. 1, 2007
Recommended INN: List 57
C35H64FN2O8PS and epimer at C* et l'épimère en C* y el epímero al C* S H3C * O H F O O N H N O CH3
CH3
O OH O P O
gamithromycinum gamithromycin
(2R,3S,4R,5S,8R,10R,11R,12S,13S,14R)-13-[(2,6-dideoxy3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10trihydroxy-3,5,8,10,12,14-hexamethyl-7-propyl-11-{[3,4,6-trideoxy3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy}-1-oxa7-azacylopentadecan-15-one (2R,3S,4R,5S,8R,10R,11R,12S,13S,14R)-13-[(2,6-didésoxy3-C-méthyl-3-O-méthyl-α-L-ribo-hexopyranosyl)oxy]-2-éthyl-3,4,10trihydroxy-3,5,8,10,12,14-hexaméthyl-7-propyl-11-[[3,4,6-tridésoxy3-(diméthylamino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa7-azacyclopentadécan-15-one (2R,3S,4R,5S,8R,10R,11R,12S,13S,14R)-13-[(2,6-didesoxi3-C-metil-3-O-metil-α-L-ribo-hexopiranosil)oxi]-2-etil-3,4,10-trihidroxi3,5,8,10,12,14-hexametil-7-propil-11-{[3,4,6-tridesoxi3-(dimetilamino)-β-D-xylo-hexopiranosil]oxi}-1-oxa7-azaciclopentadecan-15-ona C40H76N2O12 CH3 H3C H H3 C CH3 H3C N O O CH3 HO OH HO H O O CH3 OCH3 CH3 H N H HO CH3 O H O H CH3 CH3 H OH CH3 H CH3
gamithromycin
gamitromicina
ilepatrilum ilepatril
(4S,7S,12bR)-7-[(2S)-2-(acetylsulfanyl)-3-methylbutanamido]-6-oxo1,2,3,4,6,7,8,12b-octahydropyrido[2,1-a][2]benzazepine-4-carboxylic acid acide (4S,7S,12bR)-7-[[(2S)-2-(acétylsulfanyl)-3-méthylbutanoyl]= amino]-6-oxo-1,2,3,4,6,7,8,12b-octahydropyrido[2,1-a][2]= benzazépine-4-carboxylique ácido (4S,7S,12bR)-7-{[(2S)-2-(acetilsulfanil)-3-metilbutanoil]amino}6-oxo-1,2,3,4,6,7,8,12b-octahidropirido[2,1-a][2]benzazepina4-carboxílico
ilépatril
ilepatrilo
67
Recommended INN: List 57
WHO Drug Information, Vol. 21, No. 1, 2007
C22H28N2O5S CH3 O H H3C CH3 O S H H N O H N H CO2H
imisopasemum manganum imisopasem manganese
(PBPY-7-11-2344'3')-dichloro[(4aR,13aR,17aR,21aR)1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21aicosahydro-7,11-(azeno)dibenzo[b,h][1,4,7,10]= 4 5 13 18 21 22 tetraazacycloheptadecine-κ N ,N ,N ,N ,N ]manganese (PBPY-7-11-2344'3')-dichloro[(4aR,13aR,17aR,21aR)1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21aicosahydro-11,7-nitrilo-7H-dibenzo[b,h][1,4,7,10]= 5 13 18 21 22 tétraazacycloheptadécine-κN ,κN ,κN ,κN ,κN ]manganèse (PBPY-7-11-2344'3')-dicloro[(4aR,13aR,17aR,21aR)1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21aicosahidro-7,11-(azeno)dibenzo[b,h][1,4,7,10]= 4 5 13 18 21 22 tetraazacicloheptadecino-κ N ,N ,N ,N ,N ]manganeso C21H35Cl2MnN5 H N Cl N N Mn Cl N N H H
imisopasem manganèse
imisopasem manganeso
H
inakalantum inakalant inakalant
tert-butyl (2-{7-[(2S)-3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxa3,7-diazabicyclo[3.3.1]nonan-3-yl}ethyl)carbamate [2-[7-[(2S)-3-(4-cyanophénoxy)-2-hydroxypropyl]-9-oxa3,7-diazabicyclo[3.3.1]non-3-yl]éthyl]carbamate de 1,1-diméthyléthyle (2-{7-[(2S)-3-(4-cianofenoxi)-2-hidroxipropil]-9-oxa-3,7-diazabiciclo= [3.3.1]nonan-3-il}etil)carbamato de terc-butilo C23H34N4O5 NC O H OH N
inakalant
O N N H
O H3C O
CH3 CH3
68
WHO Drug Information, Vol. 21, No. 1, 2007
Recommended INN: List 57
lapaquistatum lapaquistat
(1-{[(3R,5S)-1-(3-hydroxy-2,2-dimethylpropyl)-7-chloro5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin3-yl]acetyl}piperidin-4-yl)acetic acid acide (1-{[(3R,5S)-1-(3-hydroxy-2,2-diméthylpropyl)-7-chloro5-(2,3-diméthoxyphényl)-2-oxo-1,2,3,5-tétrahydro-4,1-benzoxazépin3-yl]acétyl}pipéridin-4-yl)acétique ácido (1-{(3R,5S)-1-[3-hidroxi-2,2-dimetilpropil)]-7-cloro5-(2,3-dimetoxifenil)-2-oxo-1,2,3,5-tetrahidro-4,1-benzoxazepin3-il]acetil}piperidin-4-il)acético C31H39ClN2O8 H3C HO N O CH3 O N H OCH3 OCH3 O CO2H
lapaquistat
lapaquistat
Cl
H
levonadifloxacinum levonadifloxacin lévonadifloxacine levonadifloxacino
(5S)-9-fluoro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-6,7-dihydro1H,5H-benzo[ij]quinolizine-2-carboxylic acid (-)-acide (5S)-9-fluoro-8-(4-hydroxypipéridin-1-yl)-5-méthyl-1-oxo6,7-dihydro-1H,5H-benzo[ij]quinolizine-2-carboxylique ácido (5S)-9-fluoro-8-(4-hidroxipiperidin-1-il)-5-metil-1-oxo6,7-dihidro-1H,5H-benzo[ij]quinolizina-2-carboxílico C19H21FN2O4 HO N F O N CO2H H CH3
lexatumumabum* lexatumumab
immunoglobulin G1, anti-[human tumor necrosis factor receptor superfamily member 10B (TNFRSF10B, death receptor 5, TNFrelated apoptosis-inducing ligand receptor 2, TRAIL-R2, CD262)] human monoclonal HGS-ETR2; gamma1 heavy chain (Homo sapiens VH-IGHG1) (224-213')-disulfide with lambda light chain (Homo sapiens V-LAMBDA- IGLC2); (230-230'':233-233'')bisdisulfide dimer
69
Recommended INN: List 57
WHO Drug Information, Vol. 21, No. 1, 2007
lexatumumab
immunoglobuline G1, anti-[membre 10B de la superfamille des récepteurs du facteur de nécrose tumorale humain (TNFRSF10B, death receptor 5, TRAIL-R2, CD262)] anticorps monoclonal humain HGS-ETR2; chaîne lourde gamma1 (Homo sapiens VH-IGHG1) (224-213')-disulfure avec la chaîne légère lambda (Homo sapiens V-LAMBDA- IGLC2); dimère (230-230'':233-233'')-bisdisulfure inmunoglobulina G1, anti-[miembro 10B de la superfamilia de receptores del factor de necrosis tumoral humano (TNFRSF10B, death receptor 5, TRAIL-R2, CD262)] anticuerpo monoclonal humano HGS-ETR2; cadena pesada gamma1 (Homo sapiens VHIGHG1) (224-213')-disulfuro con la cadena ligera lambda (Homo sapiens V-LAMBDA- IGLC2); dímero (230-230'':233-233'')bisdisulfuro C6346H9832N1720O2002S42 Heavy chain / chaîne lourde / cadena pesada EVQLVQSGGG VERPGGSLRL SCAASGFTFD INWNGGSTGY ADSVKGRVTI SRDNAKNSLY GAGRGWYFDL WGKGTTVTVS SASTKGPSVF KDYFPEPVTV SWNSGALTSG VHTFPAVLQS TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PKDTLMISRT PEVTCVVVDV SHEDPEVKFN NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS K Lambda chain / chaîne lambda / cadena lambda SSELTQDPAV SVALGQTVRI TCQGDSLRSY NNRPSGIPDR FSGSSSGNTA SLTITGAQAE GGTKLTVLGQ PKAAPSVTLF PPSSEELQAN KADSSPVKAG VETTTPSKQS NNKYAASSYL GSTVEKTVAP TECS DYGMSWVRQA LQMNSLRAED PLAPSSKSTS SGLYSLSSVV PPCPAPELLG WYVDGVEVHN ALPAPIEKTI IAVEWESNGQ VMHEALHNHY PGKGLEWVSG TAVYYCAKIL GGTAALGCLV TVPSSSLGTQ GPSVFLFPPK AKTKPREEQY SKAKGQPREP PENNYKTTPP TQKSLSLSPG 50 100 150 200 250 300 350 400 450
lexatumumab
YASWYQQKPG DEADYYCNSR KATLVCLISD SLTPEQWKSH
QAPVLVIYGK DSSGNHVVFG FYPGAVTVAW RSYSCQVTHE
50 100 150 200
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 22-96 22'-87' 22''-96'' 22'''-87''' 136'-195' 136'''-195''' 148-204 148''-204'' 213'-224 213'''-224'' 230-230'' 233-233'' 265-325 265''-325'' 371-429 371''-429''
lificiguatum lificiguat lificiguat lificiguat
[5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]méthanol [5-(1-bencil-1H-indazol-3-il)furan-2-il]metanol C19H16N2O2 N O OH
N
lobeglitazonum lobeglitazone lobéglitazone lobeglitazona
(5RS)-5{[4-(2-{[6-(4-methoxyphenoxy)pyrimidin-4-yl]methylamino}= ethoxy)phenyl]methyl}-1,3-thiazolidine-2,4-dione (5RS)-5-[4-[2-[[6-(4-méthoxyphénoxy)pyrimidin-4-yl]méthylamino]= éthoxy]benzyl]thiazolidine-2,4-dione (5RS)-5-[4-(2-{[6-(4-metoxifenoxi)pirimidin-4-il]metilamino}etoxi)= bencil]-1,3-tiazolidina-2,4-diona
70
WHO Drug Information, Vol. 21, No. 1, 2007
Recommended INN: List 57
C24H24N4O5S H3CO O N N N CH3 H O S O and enantiomer et énantiomère NH y enantiómero O
lorcaserinum lorcaserin lorcasérine lorcaserina
(1R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (1R)-8-chloro-1-méthyl-2,3,4,5-tétrahydro-1H-3-benzazépine (1R)-8-cloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazepina C11H14ClN H CH3 Cl NH
mifamurtidum mifamurtide
2-[(N-{(2R)-[(2-acetamido-2,3-dideoxy-D-glucopyranos-3-yl)oxy]= propanoyl}-L-alanyl-D-isoglutaminyl-L-alanyl)amino]ethyl (2R)-2,3-bis(hexadecanoyloxy)propyl hydrogen phosphate hydrogénophosphate de 2-[[N-[(2R)-2-[(3R,4R,5S,6R)-3(acétylamino)-2,5-dihydroxy-6-(hydroxyméthyl)tétrahydro-2H-pyran4-yloxy]propanoyl]-L-alanyl-D-isoglutaminyl-L-alanyl]amino]éthyle et de (2R)-2,3-bis(hexanoyloxy)propyle hidrógenofosfato de 2-[[N-[(2R)-2-[(3R,4R,5S,6R)-3-(acetilamino)2,5-dihidroxi-6-(hidroximetil)tetrahidro-2H-piran-4-iloxi]propanoil]L-alanil-D-isoglutaminil-L-alanil]amino]etilo y de (2R)-2,3-bis(hexanoiloxi)propilo C59H109N6O19P O H HO O O HO HN O CH3 CH3 CH3 O O OH CH3 H N H O H N H NH2 H N H O N H O H O O O P O O OH
mifamurtide
mifamurtida
CH3
O
CH3
migalastatum migalastat migalastat migalastat
(2R,3S,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol (+)-(2R,3S,4R,5S)-2-(hydroxyméthyl)pipéridine-3,4,5-triol (2R,3S,4R,5S)-2-(hidroximetil)piperidina-3,4,5-triol
71
Recommended INN: List 57
WHO Drug Information, Vol. 21, No. 1, 2007
C6H13NO4 H OH H NH H OH
HO H HO
mirodenafilum mirodenafil
5-ethyl-2-(5-{[4-(2-hydroxyethyl)piperazin-1-yl]sulfonyl}2-propoxyphenyl)-7-propyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin4-one 5-éthyl-2-[5-[[4-(2-hydroxyéthyl)pipérazin-1-yl]sulfonyl]2-propoxyphenyl]-7-propyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin4-one 5-etil-2-(5-{[4-(2-hidroxietil)piperazin-1-il]sulfonil}-2-propoxifenil)7-propil-3,5-dihidro-4H-pirrolo[3,2-d]pirimidin-4-ona C26H37N5O5S O O O N HO N S O HN N CH3 CH3 N CH3
mirodénafil
mirodenafilo
motavizumabum* motavizumab
immunoglobulin G1, anti-(human respiratory syncytial virus glycoprotein F) humanized monoclonal MEDI-524; gamma1 heavy chain [humanized VH (Homo sapiens FR/Mus musculus CDR)Homo sapiens IGHG1] (223-213')-disulfide with kappa light chain [humanized V-KAPPA (Homo sapiens FR/Mus musculus CDR)Homo sapiens IGKC]; (229-229'':232-232'')-bisdisulfide dimer immunoglobuline G1, anti-(glycoprotéine de fusion du virus syncytial respiratoire humain) anticorps monoclonal humanisé MEDI-524; chaîne lourde gamma1 [VH humanisé (Homo sapiens FR/Mus musculus CDR)- Homo sapiens IGHG1] (223-213')-disulfure avec la chaîne légère kappa [V-KAPPA humanisé (Homo sapiens FR/Mus musculus CDR)-Homo sapiens IGKC]; dimère (229-229'':232-232'')bisdisulfure inmunoglobulina G1, anti-(glicoproteína de fusión del virus sincitial respiratorio humano) anticuerpo monoclonal humanizado MEDI-524; cadena pesada gamma1 [VH humanizada (Homo sapiens FR/Mus musculus CDR)- Homo sapiens IGHG1] (223-213')-disulfuro con la cadena ligera kappa [V-KAPPA humanizada (Homo sapiens FR/Mus musculus CDR)- Homo sapiens IGKC]; (229-229'':232-232'')bisdisulfide dimer
motavizumab
motavizumab
72
WHO Drug Information, Vol. 21, No. 1, 2007
Recommended INN: List 57
C6476H10014N1706O2008S48 γ-1-Chain / Chaîne γ-1 / Cadena γ-1 QVTLRESGPA LVKPTQTLTL TCTFSGFSLS ADIWWDDKKH YNPSLKDRLT ISKDTSKNQV MIFNFYFDVW GQGTTVTVSS ASTKGPSVFP DYFPEPVTVS WNSGALTSGV HTFPAVLQSS YICNVNHKPS NTKVDKRVEP KSCDKTHTCP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW STYRVVSVLT VLHQDWLNGK EYKCKVSNKA VYTLPPSREE MTKNQVSLTC LVKGFYPSDI LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV κ Chain / Chaîne κ/ Cadena κ DIQMTQSPST SKLASGVPSR TKVEIKRTVA NALQSGNSQE SSPVTKSFNR LSASVGDRVT FSGSGSGTEF APSVFIFPPS SVTEQDSKDS GEC ITCSASSRVG TLTISSLQPD DEQLKSGTAS TYSLSSTLTL YMHWYQQKPG DFATYYCFQG VVCLLNNFYP SKADYEKHKV KAPKLLIYDT SGYPFTFGGG REAKVQWKVD YACEVTHQGL 50' 100' 150' 200' 213'
TAGMSVGWIR VLKVTNMDPA LAPSSKSTSG GLYSLSSVVT PCPAPELLGG YVDGVEVHNA LPAPIEKTIS AVEWESNGQP MHEALHNHYT
QPPGKALEWL DTATYYCARD GTAALGCLVK VPSSSLGTQT PSVFLFPPKP KTKPREEQYN KAKGQPREPQ ENNYKTTPPV QKSLSLSPGK
50 100 150 200 250 300 350 400 450
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 22-97 22''-97'' 23'-87' 23'''-87''' 133'-193' 133'''-193''' 147-203 147''-203'' 213'-223 213'''-223'' 229-229'' 232-232'' 264-324 264''-324'' 370-428 370''-428''
naproxcinodum naproxcinod naproxcinod naproxcinod
4-(nitrooxy)butyl (2S)-2-(6-methoxynaphthalen-2-yl)propanoate (2S)-2-(6-méthoxynaphtalén-2-yl)propanoate de 4-(nitrooxy)butyle (2S)-2-(6-metoxinaftalen-2-il)propanoato de 4-(nitrooxi)butilo C18H21NO6 H CH3 O H3CO O O NO2
omtriptolidum omtriptolide
4-{[(3bS,4aS,5aR,6R,6aS,7aS,7bS,8aS,8bS)-8b-methyl-6a-(propan2-yl)-1-oxo-1,3,3b,4,4a,6,6a,7a,7b,8b,9,10-dodecahydrotrisoxireno= [4b,5:6,7:8a,9]phenanthro[1,2-c]furan-6-yl]oxy}-4-oxobutanoic acid acide 4-[[(3bS,4aS,5aR,6R,6aS,7aS,7bS,8aS,8bS)-8b-méthyl6a-(1-méthyléthyl)-1-oxo-1,3,3b,4,4a,6,6a,7a,7b,8b,9,10dodécahydrotrisoxiréno[4b,5:6,7:8a,9]phénanthro[1,2-c]furan-6-yl]= oxy]-4-oxobutanoïque ácido 4-{[(3bS,4aS,5aR,6R,6aS,7aS,7bS,8aS,8bS)-8b-metil6a-(propan-2-il)-1-oxo-1,3,3b,4,4a,6,6a,7a,7b,8b,9,10dodecahidrotrisoxireno[4b,5:6,7:8a,9]fenantro[1,2-c]furan-6-il]oxi}4-oxobutanoico C24H28O9 O H H3C O H O CH3 O O H O H CH3 H O
omtriptolide
omtriptolida
CO2H
73
Recommended INN: List 57
WHO Drug Information, Vol. 21, No. 1, 2007
pafuramidinum pafuramidine pafuramidine pafuramidina
4,4'-(furan-2,5-diyl)bis(N-methoxybenzenecarboximidamide) 4,4'-(furane-2,5-diyl)bis(N-méthoxybenzènecarboximidamide) 4,4'-(furano-2,5-diil)bis(N-metoxibencenocarboximidamida) C20H20N4O3 NH H3C O N H NH N H O CH3
O
pramiconazolum pramiconazole
1-(4-{4-[4-({(2S,4R)-4-(2,4-difluorophenyl)-4-[(1H-1,2,4-triazol1-yl)methyl]-1,3-dioxolan-2-yl}methoxy)phenyl]piperazin-1-yl}phenyl)3-(propan-2-yl)imidazolidin-2-one (+)-1-[4-[4-[4-[[(2S,4R)-4-(2,4-difluorophényl)-4-[(1H-1,2,4-triazol1-yl)méthyl]-1,3-dioxolan-2-yl]méthoxy]phényl]pipérazin-1-yl]phényl]3-(1-méthyléthyl)imidazolidin-2-one 1-(4-{4-[4-({(2S,4R)-4-(2,4-difluorofenil)-4-[(1H-1,2,4-triazol1-il)metil]-1,3-dioxolan-2-il}metoxi)fenil]piperazin-1-il}fenil)-3-(propan2-il)imidazolidin-2-ona C35H39F2N7O4 H N O N N N O O N N F O F
pramiconazole
pramiconazol
H3 C
N CH3
prinaberelum prinaberel prinabérel prinaberel
7-ethenyl-2-(3-fluoro-4-hydroxyphenyl)-1,3-benzoxazol-5-ol 7-éthényl-2-(3-fluoro-4-hydroxyphényl)-1,3-benzoxazol-5-ol 7-etenil-2-(3-fluoro-4-hidroxifenil)-1,3-benzoxazol-5-ol C15H10FNO3 CH2 F O OH HO N
74
WHO Drug Information, Vol. 21, No. 1, 2007
Recommended INN: List 57
rilonaceptum* rilonacept
[653-glycine][human interleukin-1 receptor accessory protein(1-339)-peptide (extracellular domain fragment) fusion protein with human type 1 interleukin-1 receptor-(5-316)-peptide (extracellular domain fragment) fusion protein with human immunoglobulin G1(229 C-terminal residues)-peptide (Fc fragment)], (659-659':662662')-bisdisulfide dimer (659-659':662-662')-bisdisulfure du dimère de la [653-glycine][protéine accessoire du récepteur de l’interleukine-1 humaine-(1-339)-peptide (fragment du domaine extracellulaire) protéine de fusion avec le récepteur de type I humain de l’interleukine-1-(5-316)-peptide (fragment du domaine extracellulaire) protéine de fusion avec l’immunoglobuline G1 humaine-(229 résidus C-terminaux)-peptide (fragment Fc)] (659-659':662-662')-bisdisulfuro del dímero de la [653-glicina][proteína accesoria del receptor de la interleukina-1 humana-(1-339)-péptido (fragmento del dominio extracelular) proteína de fusión con el receptor de tipo I humano de la interleukina-1-(5-316)-péptido (fragmento del dominio extracelular) proteína de fusión con la inmunoglobulina G1 humana-(229 restos C-terminales)-péptido (fragmento Fc)] C9030H13932N2400O2670S74 Monomer / Monomère / Monómero SERCDDWGLD TMRQIQVFED EPARIKCPLF YWTRQDRDLE EPINFRLPEN RISKEKDVLW YCSKVAFPLE VVQKDSCFNS PMKLPVHKLY VKPTITWYMG CYKIQNFNNV IPEGMNLSFL RTFHLTRTLT VKVVGSPKNA VPPVIHSPND SFLMDSRNEV WWTIDGKKPD DITIDVTINE VTSEDLKRSY VCHARSAKGE VAKAAKVKQK VSSANEIDVR PCPLNPNEHK GTITWYKDDS FVPAKVEDSG HYYCVVRNSS YCLRIKISAK PVAGDGGLVC PYMEFFKNEN NELPKLQWYK VMNVAEKHRG NYTCHASYTY LGKQYPITRV NETMEVDLGS QIQLICNVTG QLSDIAYWKW NPANKRRSTL ITVLNISEIE SRFYKHPFTC NSGDKTHTCP PCPAPELLGG PSVFLFPPKP HEDPEVKFNW YVDGVEVHNA KTKPREEQYN EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ LVKGFYPSDI AVEWESNGQP ENNYKTTPPV QQGNVFSCSV MHEALHNHYT QKSLSLSPGK EHFLKFNYST FRPTLLNDTG IEYGIQRITC IALISNNGNY HVVYEKEPGE SISHSRTEDE VPAPRYTVEK KTPVSTEQAS FVENEPNLCY DCKPLLLDNI IEFITLEENK NGSVIDEDDP FAKNTHGIDA KDTLMISRTP STYRVVSVLT VYTLPPSRDE LDSDGSFFLY AHSAGLTLIW NYTCMLRNTT PNVDGYFPSS TCVVTYPENG ELLIPCTVYF TRTQILSIKK CKEREEKIIL RIHQHKEKLW NAQAIFKQKL HFSGVKDRLI PTRPVIVSPA VLGEDYYSVE AYIQLIYPVT EVTCVVVDVS VLHQDWLNGK LTKNQVSLTC SKLTVDKSRW 50 100 150 200 250 300 350 400 450 500 550 600 650 700 750 800 850 880
rilonacept
rilonacept
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 4-102 4'-102' 27-94 27'-94' 117-161 117'-161' 140-192 140'-192' 246-312 246'-312' 341-422 341'-422' 362-414 362'-414' 339-482 339'-482' 460-514 460'-514' 566-630 566'-630' 659-659' 662-662' 694-754 694'-754' 800-858 800'-858'
rosabulinum rosabulin rosabuline rosabulina
2-{3-[(4-cyanophenyl)methyl]indolizin-1-yl}-N-(3-methyl-1,2-thiazol5-yl)-2-oxoacetamide 2-[3-(4-cyanobenzyl)indolizin-1-yl]-N-(3-méthylisothiazol-5-yl)2-oxoacétamide 2-{3-[(4-cianofenil)metil]indolizin-1-il}-N-(3-metilisotiazol-5-il)2-oxoacetamida
75
Recommended INN: List 57
WHO Drug Information, Vol. 21, No. 1, 2007
C22H16N4O2S O N O NC CH3 H N
S N
sagopilonum sagopilone
(1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,12,16-tetramethyl3-(2-methyl-1,3-benzothiazol-5-yl)-10-(prop-2-enyl)4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione (-)-(1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,12,16tétraméthyl-3-(2-méthyl-1,3-benzothiazol-5-yl]-10-(prop-2-ényl)4,17-dioxabicyclo[14.1.0]heptadécane-5,9-dione (1S,3S,7S,10R,11S,12S,16R)-7,11-dihidroxi-8,8,12,16-tetrametil3-(2-metil-1,3-benzotiazol-5-il)-10-(prop-2-enil)4,17-dioxabiciclo[14.1.0]heptadecano-5,9-diona C30H41NO6S H3C H H O H S CH3 N O O H
sagopilone
sagopilona
HO H H2C
CH3 H3C CH3 O H OH
sodelglitazarum sodelglitazar sodelglitazar
2-{4-[({2-[2-fluoro-4-(trifluromethyl)phenyl]-4-methyl-1,3-thiazol5-yl}methyl)sulfanyl]-2-methylphenoxy}-2-methylpropanoic acid acide 2-[4-[[[2-[2-fluoro-4-(trifluorométhyl)phényl]-4-méthyl1,3-thiazol-5-yl]méthyl]sulfanyl]-2-méthylphénoxy]2-méthylpropanoïque ácido 2-{4-[({2-[2-fluoro-4-(trifluorometil)fenil]-4-metil-1,3-tiazol5-il}metil)sulfanil]-2-metilfenoxi}-2-metilpropanoico C23H21F4NO3S2 N F3C S F CH3 CH3 S
sodelglitazar
H3 C O
CH3 CO2H
76
WHO Drug Information, Vol. 21, No. 1, 2007
Recommended INN: List 57
sofigatranum sofigatran
propyl {(1S)-1-{(2S)-2-[(trans-4-aminocyclohexylmethyl)carbamoyl]= pyrrolidine-1-carbonyl}-2-methyl-2-[(propan-2-yl)sulfanyl]propyl}= carbamate [(1S)-1-[[(2S)-2-[[(trans-4-aminocyclohexyl)méthyl]carbamoyl]= pyrrolidin-1-yl]carbonyl]-2-méthyl-2-[(1-méthyléthyl)sulfanyl]propyl]= carbamate de propyle [(1S)-1-[[(2S)-2-[[(trans-4-aminociclohexil)metil]carbamoil]pyrrolidin1-il]carbonil]-2-metil-2-[(propan-2-il)sulfanil]propil]carbamato de propilo C24H44N4O4S H3C H2N H N O H O HN N H O CH3 S CH3 CH3 O CH3
sofigatran
sofigatrán
succinobucolum succinobucol succinobucol
4-{4-[(2-{[3,5-di(tert-butyl)-4-hydroxyphenyl]sulfanyl}propan-2-yl)= sulfanyl]-2,6-di(tert-butyl)phenoxy}-4-oxobutanoic acid acide 4-[4-[[1-[[3,5-bis(1,1-diméthyléthyl)-4-hydroxyphényl]sulfanyl]1-méthyléthyl]sulfanyl]-2,6-bis(1,1-diméthyléthyl)phénoxy]4-oxobutanoïque ácido 4-{4-[(2-{[3,5-di(terc-butil)4-hidroxifenil]sulfanil}propan-2-il)= sulfanil]-2,6-di(terc-butil)fenoxi}-4-oxobutanoico C35H52O5S2 H3 C HO H3C H3C CH3 CH3 CH3 H3C S H3 C H3 C CH3 S H3C CH3 O CH3 CH3 O CO2H
succinobucol
taribavirinum taribavirin taribavirine taribavirina
1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboximidamide 1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboximidamide 1-β-D-ribofuranosil-1H-1,2,4-triazol-3-carboximidamida
77
Recommended INN: List 57
WHO Drug Information, Vol. 21, No. 1, 2007
C8H13N5O4 NH2 HN HO O N N N
OH
OH
tezampanelum tezampanel tézampanel tezampanel
(3S,4aR,6R,8aR)-6-[2-(1H-tetrazol-5-yl)ethyl]decahydroisoquinoline3-carboxylic acid (-)-acide (3S,4aR,6R,8aR)-6-[2-(1H-tétrazol-5-yl)éthyl]= décahydroisoquinoléine-3-carboxylique (-)-ácido (3S,4aR,6R,8aR)-6-[2-(1H-tetrazol-5-il)etil]= decahidroisoquinolina-3-carboxílico C13H21N5O2 N N N N H H NH H H H CO2H
ticagrelorum ticagrelor
(1S,2S,3R,5S)-3-(7-{[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]= amino}-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)5-(2-hydroxyethoxy)cyclopentane-1,2-diol (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophényl)cyclopropyl]= amino]-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]5-(2-hydroxyéthoxy)cyclopentane-1,2-diol (1S,2S,3R,5S)-3-(7-{[(1R,2S)-2-(3,4-difluorofenil)ciclopropil]amino}5-(propilsulfanil)-3H-[1,2,3]triazolo[4,5-d]pirimidin-3-il)5-(2-hidroxietoxi)ciclopentano-1,2-diol C23H28F2N6O4S H3C S N OH OH N H H HO O H H N N N NH H H F F
ticagrélor
ticagrelor
78
WHO Drug Information, Vol. 21, No. 1, 2007
Recommended INN: List 57
tigapotidum tigapotide
L-glutamyl-L-tryptophyl-L-glutaminyl-L-threonyl-L-aspartylL-asparaginyl-S-[(acetamido)methyl]-L-cysteinyl-L-glutamylL-threonyl-S-[(acetamido)methyl]-L-cysteinyl-L-threonylS-[(acetamido)methyl]-L-cysteinyl-L-tyrosyl-L-glutamyl-L-threonine
tigapotide tigapotida
S -S ,S -tris[(acétylamino)méthyl]bêta-microséminoprotéine humaine (protéine PSP94 sécrétée par la prostate)-(31-45)-peptide S -S ,S -tris[(aceltilamino)metil]beta-microseminoproteína humana (proteína PSP94 secretada por la próstata)-(31-45)-péptido C82H119N21O34S3 O HN S 37 40 42
37
40
42
CH3
O HN S
CH3
O NH S
CH3
H Glu Trp Gln Thr Asp Asn Cys Glu Thr Cys Thr Cys Tyr Glu Thr OH
tipelukastum tipelukast tipélukast tipelukast
4-(6-acetyl-3-{3-[(4-acetyl-3-hydroxy-2-propylphenyl)sulfanyl]= propoxy}-2-propylphenoxy)butanoic acid acide 4-[6-acétyl-3-[3-[(4-acétyl-3-hydroxy-2-propylphényl)sulfanyl]= propoxy]-2-propylphénoxy]butanoïque ácido 4-[6-acetil-3-[3-[(4-acetil-3-hidroxi-2-propilfenil)sulfanil]= propoxi]-2-propilfenoxi]butanoico C29H38O7S O H3 C HO S O O O CH3 CO2H
CH3
CH3
tomopenemum tomopenem
(4R,5S,6S)-3-({(3S,5S)-5-[(3S)-3-(carbamimidamidoacetamido)= pyrrolidine-1-carbonyl]-1-methylpyrrolidin-3-yl}sulfanyl)6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept2-ene-2-carboxylic acid (-)-acide (4R,5S,6S)-3-[[(3S,5S)-5-[[(3S)-3-[[(carbamimidoylamino)= acétyl]amino]pyrrolidin-1-yl]carbonyl]-1-méthylpyrrolidin-3-yl]= sulfanyl]-6-[(1R)-1-hydroxyéthyl]-4-méthyl-7-oxo-1-azabicyclo[3.2.0]= hept-2-ène-2-carboxylique ácido (4R,5S,6S)-3-{[(3S,5S)-5-({(3S)-3(carbamimidamidoacetamido)pirrolidin-1-il}carbonil)-1-metilpirrolidin3-il]sulfanil}-6-[(1R)-1-hidroxietil]-4-metil-7-oxo-1-azabiciclo[3.2.0]= hept-2-eno-2-carboxílico
tomopénem
tomopenem
79
Recommended INN: List 57
WHO Drug Information, Vol. 21, No. 1, 2007
C23H35N7O6S O H3C HO H H N H H CO2H S H CH3 O N N H CH3 H N H O N H NH NH2
tylvalosinum tylvalosin
(4R,5S,6S,7R,9R,11E,13E,15R,16R)-15-{[(6-deoxy-2,3-di-O-methylβ-D-allopyranosyl)oxy]methyl}-6-({3,6-dideoxy-4-O-[2,6-dideoxy3-C-methyl-4-O-(3-methylbutanoyl)-α-L-ribo-hexopyranosyl]3-(dimethylamino)-β-D-glucopyranosyl}oxy)-16-ethyl-5,9,13-trimethyl2,10-dioxo-7-(2-oxoethyl)oxacyclohexadeca-11,13-dien-4-yl acetate (-)-acétate de (4R,5S,6S,7R,9R,11E,13E,15R,16R)-15-[[(6-désoxy2,3-di-O-méthyl-β-D-allopyranosyl)oxy]méthyl]-6-[[3,6-didésoxy4-O-[2,6-didésoxy-3-C-méthyl-4-O-(3-méthylbutanoyl)-α-L-ribohexopyranosyl]-3-(diméthylamino)-β-D-glucopyranosyl]oxy]-16-éthyl5,9,13-triméthyl-2,10-dioxo-7-(2-oxoéthyl)oxacyclohexadéca11,13-dién-4-yle (-)-acetato de (4R,5S,6S,7R,9R,11E,13E,15R,16R)-15-[[(6-desoxi2,3-di-O-metil-β-D-alopiranosil)oxi]metil]-6-[[3,6-didesoxi4-O-[2,6-didesoxi-3-C-metil-4-O-(3-metilbutanoil)-α-L-ribohexopiranosil]-3-(dimetilamino)-β-D-glucopiranosil]oxi]-16-etil5,9,13-trimetil-2,10-dioxo-7-(2-oxoetil)oxaciclohexadeca-11,13-dien4-ilo C53H87NO19 H3C H H H O OH O H CH3 O
tylvalosine
tilvalosina
OHC CH3 H3C O O CH3 OH CH3 H3C O O CH3 N O O CH3
CH3 CH3 H O O H3C HO H3CO OCH3 H H CH3 O
O
vabicaserinum vabicaserin vabicasérine vabicaserina
(9aR*,12aS*)-4,5,6,7,9,9a,10,11,12,12adecahydrocyclopenta[c][1,4]diazepino[6,7,1-ij]quinoline (-)-(9aR*,12aS*)-4,5,6,7,9,9a,10,11,12,12adécahydrocyclopenta[c][1,4]diazepino[6,7,1-ij]quinoléine (-)-(9aR*,12aS*)-4,5,6,7,9,9a,10,11,12,12adecahidrociclopenta[c][1,4]diazepino[6,7,1-ij]quinolina
80
WHO Drug Information, Vol. 21, No. 1, 2007
Recommended INN: List 57
C15H20N2 H N H NH
or enantiomer, (-)-isomer ou énantiomère, (-)-isomère o enantiómero, (-)-isómero
vapitadinum vapitadine vapitadine vapitadina
5,6-dihydrospiro(imidazo[2,1-b][3]benzazepine-11,4'-piperidine)3-carboxamide 5,6-dihydrospiro[11H-imidazo[2,1-b][3]benzazépine-11,4'-pipéridine]3-carboxamide 5,6-dihidrospiro(11H-imidazo[2,1-b][3]benzazepina-11,4'-piperidina)3-carboxamida C17H20N4O
NH
N H2N O
N
veliflaponum veliflapon véliflapon veliflapón
(2R)-cyclopentyl{4-[(quinolin-2-yl)methoxy]phenyl}acetic acid (+)-acide (2R)-cyclopentyl[4-(quinoléin-2-ylméthoxy)phényl]acétique (+)-ácido (2R)-ciclopentil[4-(quinolin-2-ilmetoxi)fenil]acético C23H23NO3 H CO2H
N
O
volinanserinum volinanserin volinansérine volinanserina
(R)-(2,3-dimethoxyphenyl){1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl}= methanol (+)-(R)-(2,3-diméthoxyphényl)[1-[2-(4-fluorophényl)éthyl]pipéridin4-yl]méthanol (+)-(R)-(2,3-dimetoxifenil)[1-[2-(4-fluorofenil)etil]piperidin-4-il]metanol
81
Recommended INN: List 57
WHO Drug Information, Vol. 21, No. 1, 2007
C22H28FNO3 F N H3CO OCH3
H OH
AMENDMENTS TO PREVIOUS LISTS MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES MODIFICACIONES A LAS LISTAS ANTERIORES
Recommended International Non Proprietary Names (Rec. INN): List 53 Dénominations communes internationales recommandées (DCI Rec.): Liste 53 Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 53 (WHO Drug Information, Vol. 19, No. 1, 2005) p. 80 delete/supprimer/suprímase gantacurium chloridum panitumumabun panitumumab panitumumab panitumumab insert/insérer/insertése gantacurii chloridum
p. 88
replace the molecular formula by the following remplacer la formule brute par la suivante sustitúyase la fórmula molecular por la siguiente C6398H9878N1694O2016S48
p. 88
pelitinibum pelitinib
sustitúyase el nombre químico por el siguiente: (2E)-N-[3-ciano-4-[(3-cloro-4-fluorofenil)amino]-7-etoxiquinolin-6-il]4-(dimetilamino)-2-butenamina
Recommended International Non Proprietary Names (Rec. INN): List 55 Dénominations communes internationales recommandées (DCI Rec.): Liste 55 Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 55 (WHO Drug Information, Vol. 20, No. 1, 2006) p. 45 suprimáse nebicapone insértese nebicapona
* Electronic structure available on Mednet: http://mednet.who.int/ * Structure électronique disponible sur Mednet: http://mednet.who.int/ * Estructura electrónica disponible en Mednet: http://mednet.who.int/ 82
WHO Drug Information, Vol. 21, No. 1, 2007
Recommended INN: List 57
Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances will be reproduced in proposed INN lists only. Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques seront publiés seulement dans les listes des DCI proposées. El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas aparece solamente en las listas de DCI propuestas.
83